KalVista re­ports PhI­II suc­cess of on-de­mand, oral hered­i­tary an­gioede­ma drug as it seeks to chal­lenge in­jecta­bles

KalVista Phar­ma­ceu­ti­cals’ oral med­i­cine for hered­i­tary an­gioede­ma helped re­lieve at­tack symp­toms as­so­ci­at­ed with the dis­ease sub­stan­tial­ly faster than place­bo in a late-stage study, set­ting the com­pa­ny up to sub­mit for an FDA ap­proval this year.

In hered­i­tary an­gioede­ma, or HAE for short, peo­ple ex­pe­ri­ence se­vere swelling at­tacks. Cur­rent­ly, the at­tacks are treat­ed with in­jectable med­i­cines such as Take­da’s Fi­razyr, but KalVista hopes its pill can pro­vide an eas­i­er and po­ten­tial­ly quick­er op­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER